A Risk-Benefit Assessment of Naltrexone in the Treatment of Alcohol Dependence
- 42 Downloads
There is a great deal of interest in the use of naltrexone as a treatment for alcohol (ethanol) dependence since there is a rapidly expanding body of evidence to support its efficacy and tolerability in this indication. Naltrexone, a long-acting, nonselective opioid receptor antagonist has been shown to reduce alcohol intake when combined with behavioural treatment. Naltrexone may prevent the return to clinically significant drinking by blocking the pleasurable effects or ‘high’ associated with alcohol drinking. Results from controlled studies showed that in alcohol dependent patients taking naltrexone 50 mg/day in combination with behavioural treatment, relapse rates were reduced by 50% compared with placebo treated patients.
Historically, several factors have limited the use of effective pharmacological adjuncts in the treatment of alcohol dependence. These include safety considerations in this vulnerable population, and the fact that some treatment programmes discourage alcohol-dependent patients from taking medications. The most common adverse effects reported with the use of naltrexone at a dosage of 50 mg/day include nausea and vomiting. Naltrexone does not appear to be hepatotoxic in dosages recommended in the treatment of alcohol dependence, i.e. 50 mg/day. Thus, naltrexone appears to offer significant therapeutic benefits at a relatively low risk, when used judiciously and with behavioural treatment for alcohol dependent patients.
KeywordsOpioid Receptor Alcohol Dependence Naltrexone Disulfiram Oxymorphone
Unable to display preview. Download preview PDF.
- 1.Volpicelli JR, O’Brien CP, Arthur AI, et al. Naltrexone and the treatment of alcohol-dependence: initial observations. In: Reid LD, editor. Opioids, bulimia, and alcohol abuse & alcoholism. New York: Springer-Verlag, 1990Google Scholar
- 9.Data on file, DuPont MerckGoogle Scholar
- 10.Malcolm R, O’Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obesity 1985; 9: 347–53Google Scholar
- 13.Marrazzi MA, Markham KM, Kinzie J, et al. Binge eating disorder: response to naltrexone. Int J Obesity 1995; 19(2); 143–5Google Scholar
- 14.Pfohl DN, Allen JI, Atkinson RL, et al. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. In: Harris LS, editor. Problems on drug dependence. Proceedings of the 47th Annual Scientific Meeting of the Committee on Problems of Alcohol Dependence, 1985 Jun 8–13. Rockville: The Committee on Problems of Drug Dependence, Inc. National Institute on Drug Abuse, Office of Science, 1986; 66–72 (National Institute on Drug Abuse Research Monograph; 67)Google Scholar
- 23.Verebey K, Mule SJ. Naltrexone and β-naltrexol plasma levels in schizophrenic patients. Res Commun Psychol Psychiatry Behav 1979; 4(3): 311–7Google Scholar
- 24.Reisine T, Pasternak G. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. Goodman & Gilman’s pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996Google Scholar
- 42.Gilmore R, Hack R, Kuhn R, et al. Naltrexone-associated decrease in phenytoin concentration [letter]. Epilepsia 1989; 3(5): 738Google Scholar
- 44.Physicians’ Desk Reference. 50th ed. Montvale (NJ): Medical Economics Co., 1996Google Scholar